drugset / Trial / NCT07335913
Phase 1 Study of SBS-147 in Healthy Adults
Phase 1
Recruiting
80 enrolled
Sparian Biosciences, Inc
Altasciences Company Inc. · collabNational Institutes of Health (NIH) · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.
Timeline
- Start
- 2026-01-08
- Primary completion
- 2027-01-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SBS-147 | Unknown | — | Oral |
Indications
No indication recorded.